Skip to main content

Kim L. R. Brouwer

Associate Dean William R. Kenan, Jr. Dist. Professor

Kim Brouwer, Pharm.D., Ph.D.

Associate Dean

William R. Kenan, Jr. Distinguished Professor


kim_brouwer

PHONE
(919) 962-7030
EMAIL
kbrouwer@unc.edu
ADDRESS
100 L Beard Hall, UNC Eshelman School Of Pharmacy, CB# 7569, Chapel Hill, NC, 27599-7569
DOWNLOAD CV

RECRUITING GRADUATE STUDENTS

Kim L.R. Brouwer, Pharm.D., Ph.D., is the William R. Kenan Jr. Distinguished Professor in the Division of Pharmacotherapy and Experimental Therapeutics at the UNC Eshelman School of Pharmacy, associate dean for research and graduate education, and a professor in the curriculum in toxicology.

Brouwer received her B.S. in pharmacy from Oregon State University. She completed her Pharm.D. at the University of Kentucky (UK) College of Pharmacy in conjunction with a pharmacy residency at the UK Medical Center and a PhD in pharmaceutical sciences/pharmacokinetics. After postdoctoral training (pharmacology/drug metabolism) in the UK College of Medicine, she joined the faculty at the University of North Carolina in 1986, where she served as director of graduate studies for the UNC Eshelman School of Pharmacy from 1996 to 2004, and Chair of the Division of Pharmacotherapy and Experimental Therapeutics from 2004-2015.

Brouwer directs an NIH-funded research program focused on hepatobiliary drug disposition and development and refinement of in vitro model systems to predict in vivo hepatobiliary disposition, drug interactions, and hepatotoxicity. She has mentored more than 104 undergraduate, professional, graduate and postdoctoral students and published more than 230 research papers, reviews and book chapters in addition to more than 240 published abstracts.

Brouwer is also a co-inventor of B-CLEAR® (U.S. Patent No. 6,780,580), an in vitro method to assess hepatic uptake, excretion, and biliary clearance that correlates with in vivo data. This technology has been exclusively licensed from the University of North Carolina at Chapel Hill to Qualyst, Inc. Brouwer is a Qualystco-founder and former chair of the company’s scientific advisory board. Qualyst Transporter Solutions was acquired by BioIVT in August 2017.

She served as a member of the NIH Pharmacology Study Section from 1998 to 2002, and is a member of the editorial advisory boards for Clinical Pharmacology and Therapeutics, CPT Pharmacometrics & Systems Pharmacology, Clinical and Translational Science, and the AAPS Journal. She was elected an AAPS Fellow in 1998, was recipient of the PHRMA Foundation Award in Excellence in Pharmaceutics in 2001, received the inaugural Pharmaceutical Sciences Outstanding Graduate Program Alumni Award and the Paul F. Parker Award from the University of Kentucky, and was the recipient of the 2018 ASCPT-FDA Abrams Award.

Research

  • Mechanisms of hepatic uptake, translocation and biliary excretion
  • Drug transport
  • Pharmacokinetics
  • Aberrant gastrointestinal drug absorption phenomena

Dr. Brouwer directs an NIH-funded research program focused on hepatobiliary drug disposition and development and refinement of in vitro model systems to predict in vivo hepatobiliary disposition, drug interactions, and hepatotoxicity. She is a co-inventor of B-CLEAR® (U.S. Patent No. 6,780,580), an in vitro method to assess hepatic uptake, excretion, and biliary clearance that correlates with in vivo data. This technology has been exclusively licensed from the University of North Carolina at Chapel Hill to Qualyst, Inc. Dr. Brouwer is a Qualyst founder and chairs the company’s scientific advisory board.

Learn More About the Brouwer Lab

  • Mechanisms of Altered Hepatic Transport: Impact on Drug Therapy
  • UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program

  • Ph.D., University of Kentucky
  • Pharm.D., University of Kentucky
  • B.S., Oregon State University

Kim Brouwer News